|Mr. John J. Nicols||Pres, CEO & Director||1.12M||N/A||1964|
|Mr. Gordon T. B. Sangster||Sr. VP & CFO||591.21k||N/A||1953|
|Mr. Michael D. A. Aldridge B.Sc (Hons)., MApFin||Sr. VP of Corp. & Strategic Devel.||125.01k||N/A||1967|
|Dr. James J. Lalonde Ph.D.||Sr. VP of R&D||480.54k||N/A||1961|
|Mr. Keith McKay||Director of Bus. Devel.||N/A||N/A||N/A|
Codexis, Inc. discovers, develops, and sells protein catalysts. It also offers intermediate chemicals products that are used for further chemical processing; and Codex biocatalyst panels and kits that enable customers to perform chemistry screening. The company also provides protein catalyst screening and protein engineering services. In addition, it offers CodeEvolver protein engineering technology platform, which helps in developing and delivering protein catalysts that perform chemical transformations. The company's platform is used to discover novel biotherapeutic drug candidates for targeted human diseases, as well as for molecular biology and in vitro diagnostic enzymes. Its platform also enhances the pharmaceuticals companies manufacturing productivity and efficiency or outsourcing the manufacture of the intermediates and active pharmaceutical ingredients. The company sells its products to pharmaceutical manufacturers through its direct sales and business development force in the United States and Europe. Codexis, Inc. was founded in 2002 and is headquartered in Redwood City, California.
Codexis, Inc.’s ISS Governance QualityScore as of March 1, 2018 is 5. The pillar scores are Audit: 2; Board: 2; Shareholder Rights: 7; Compensation: 8.